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Summary The prevalence of human papillomavirus (HPV) infection and other risk factors were studied in a high risk area for cervical cancer (Greenland) and in a low risk area (Denmark). From Nuuk (Greenland) and Nykobing Falster (Denmark), random samples of 150 women aged 20-39 years were drawn. A total of 129 and 126 women were included in Greenland and Denmark, respectively. The proportion of HPV infected
women assessed by ViraPap was similar in Denmark and Greenland (4.8 vs 3.9%). When type specific polymerase chain reaction (PCR) was used, the total HPV detection rate was 38.9% in the Danish population and 43.4% in the Greenlandic. A similar interrelationship between Greenland and Denmark applied to the HPV types 11, 16, 18 and 33. No relationship was observed between HPV detection and number of partners for any of the diagnostic methods. Significantly more Greenlandic than Danish women had antibodies to HSV 2, 76.0% and 26.2%, respectively. The prevalence of self-reported histories of selected venereal diseases was also highest among Greenlanders, except for genital warts where the prevalence was similar in the two areas. Greenlandic women had significantly more sexual partners, earlier age at first -intercourse, more current smokers and less use of barrier contraceptives compared to the Danish women. This study confirms the results of our previous population-based cross-sectional comparison study in these areas, corroborating the conc- lusion that the prevalence of detectable HPV infection does not seem to be a determinant of cervical cancer incidence. However, by using DNA hybridisation techniques, temporal virus shedding is only measured at one point in time. Detectable virus shedding may not correlate with the risk of cervical cancer. In fact, HPV DNA detection may have different implications in different populations. In Denmark, HPV DNA detection may reflect transient, recently acquired infection, whereas in Greenland, it is more indicative of chronic persistent infection.
Epidemiological research has long pointed to cancer of the
cervix uteri as a sexually transmitted disease (Brinton &
Fraumeni, 1986). For more than a decade, human papil-
lomavirus (HPV) has been suggested to play an important
role in cervical carcinogenesis (zur Hausen, 1989). Not only
has HPV DNA been detected in more than 90% of all
cervical carcinoma samples tested, but it has also recently
been shown that human keratinocytes immortalised with
HPV DNA, turn malignant after prolonged cultivation (Hur-
lin et al., 1991; Pecoraro et al., 1991). If HPV is a main
causal agent, one would anticipate a geographical accordance
between incidence of cervical cancer and prevalence of HPV
infection. On this background we were surprised that our
population-based comparison showed that the prevalence of
HPV 16/18 detection was higher in Denmark (13.0%) than in
Greenland (8.8%) in spite of the cervical cancer incidence
being five times higher in Greenland (Kjaer et al., 1988). By
contrast, the high risk Greenlandic women were characterised
by e.g. a higher number of sexual partners and earlier age at
first intercourse compared with Danish women (Kjaer et al.,
1989). Because of the surprising lack of correspondence
between HPV 16/18 prevalence and incidence of cervical
cancer and in view of the further development of new DNA
hybridisation techniques, we decided to undertake a renewed
comparative study in the same geographical areas. In addi-
tion, we reinvestigated the association between HPV and
HSV infection and the number of sexual partners like in the
previous investigation (Kjaer et al., 1990).
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Material and methods
Studypopulation
From October to November 1988, a population-based cross-
sectional study was conducted in Nuuk, Greenland and in
Nyk0bing Falster, Denmark. In contrast to the Danish
population, which is essentially Caucasian, the Greenlandic
people is of Inuit origin with an approximately 25-30%
admixture of Caucasians (Kissmeyer-Nielsen et al., 1971). The cumulative incidence rate of cervical cancer is 5.7 times
higher in Greenland than in Denmark for women 20-39
years of age (Kjaer et al., 1988).
The study comprised 150 women (20-39 years of age) born in Greenland and with residence in Nuuk, and 150
women (20-39 years old) born in Denmark, resident in the
municipality of Nyk0bing Falster. The study populations
were drawn at random from the computerised Danish Cent-
ral Population Register. The procedure of enrolment was
identical to that of the first study, and a detailed description has been provided previously (Kjaer et al., 1988). In Greenland, 17 women had moved out of the area prior to enrolment, leaving 133 eligible for study. Of these, 129
women (97.0%) were included (Table I), three (2.3%) did not
want to participate, and one women (0.8%) could not be
reached. In Denmark, a total of 144 women were eligible for
investigation (six had moved before contact). We succeeded
in including 126 women (87.5%) (Table I), 11 (7.6%) did not
want to participate, and seven (4.9%) could not be con-
tacted. Table I also shows that the age distributions are
nearly identical in the studies from 1986 and 1988, respec- tively. The number of women who participated in both
studies was 48 and 21 women in Greenland and Denmark, respectively. This is not more than expected from the sizes of
populations and random samples.
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Table I Female population (20-39 years of age) of Nyk0bing Falster (Denmark) and Nuuk (Greenland), and study
participants in the first study (1986) and in the second study (1988)
Nykobing Faister, Denmark Nuuk, Greenland
Totalfemale 1. study (1986) 2. study (1988) Totalfemale 1. study (1986) 2. study (1988)
Age population participants participants population participants participants
(years) n (%) n (%) n (%) n (%) n (%) n (%)
20-24 975 (27.9) 166 (25.1) 32 (25.4) 582 (37.0) 193 (32.9) 43 (33.3)
25-29 774 (22.2) 132 (20.0) 26 (20.6) 439 (27.9) 171 (29.7) 35 (27.1)
30-34 825 (23.6) 172 (26.0) 34 (27.0) 328 (20.8) 127 (21.7) 32 (24.8)
35-39 920 (26.3) 191 (28.9) 34 (27.0) 225 (14.3) 95 (16.2) 19 (14.7)
Total 3494 (100.0) 661 (100.0) 126 (100.0) 1574 (100.0) 586 (100.0) 129 (100.0)
Data collection
Independently of study area, a random study number from 1
to 300 was allocated to each woman. The code was deposited
at the Danish Cancer Registry and was not broken until all
data had been computerised. An ad hoc field team consisting
of a female doctor (Greenland: BJH; Denmark: ES) and a
nurse in each area conducted a personal interview, undertook
a gynaecological examination and drew a blood sample from
every participating woman.
Interviews All interviews were conducted by the same local
field team by means of a structured questionnaire on marital
status, education, occupation, smoking, use ofcontraception,
previous Pap smears, gynaecological surgery, history of sex-
ually transmitted diseases, age at first intercourse, lifetime
number of sexual partners and selected dietary habits. Every
effort was made to ensure that the interviews as well as the
gynaecological examinations were performed in the same way
in the two areas.
Biological samples All the participants had a complete
gynaecological examination. Cells for HPV investigation were
sampled using two cotton-tipped swabs. The first was scraped
over the entire surface of the cervix, and the second swab
was rotated in the endocervical canal. Both swabs were
placed in the same plastic tube, containing 2 ml of TE buffer.
The samples were immediately deep frozen at - 30°C and
stored until forwarded on dry ice to the German Cancer
Research Center, Heidelberg.
Subsequently, a Papanicolaou (Pap) smear was taken, em-
ploying standard techniques and by means of an Ayre's
spatula and a cytobrush for the cervical surface and endocer-
vical canal, respectively. Slides were then included in the
routine cytological diagnostic procedure of the participating
pathological departments.
Finally, two blood samples were drawn from each woman.
The serum was separated and sent to the Seruminstitut in
Copenhagen for investigation of presence of HSV type-
specific antibodies.
Laboratory analyses
Human papillomavirus ViraPap/ViraType - the ViraPapR
and ViraTypeTM commercial tests (Life Technologies, Inc.)
were used as the first method for the detection of HPV
DNA. Each cell pellet was resuspended in the ViraPap Speci-
men Transport Medium and divided into two samples, after
which the tests were performed according to the instructions
as decribed by the manufacturers. This included disruption of
the cells and viral particles with subsequent denaturation of
the DNA. The DNA was then immobilised on a nylon-
membrane and hybridised with [32P]-labelled RNA probes
provided by the manufacturers. The probes consisted of a
mixture of HPV types 6, 11, 16, 18, 31, 33 and 35 in the case
of ViraPapR and three separate probes of HPV 6/11, HPV
16/18 and HPV 31/33/35 in the ViraTypeT test. The
presence of specifically bound RNA probe was detected by
autoradiography.
Polymerase chain reaction (PCR) The samples were tested
for the presence of HPV 11, 16, 18 and 33 DNA. The
nucleotide sequences used as primers were selected from the
E6/E7 region of each genome (Dartmann et al., 1986;
Seedorf et al., 1985; Cole & Danos, 1987; Cole & Streek,
1986). The localisation of the primers were such that amp-
limers of the respective HPV types could be identified accord-
ing to their size on agarose gels (Whitcomb et al., 1989).
Amplification reactions were performed in groups of 20
samples, each time including a positive (100 pg purified HPV
plasmid DNA plus 100 ng carrier DNA) as well as a negative
(sperm DNA) control.
Cells obtained from each cervical smear were lysed with
SDS and digested with Proteinase K. After subsequent
phenol extraction, the DNA was precipitated and pellets
resuspended at 50fg ml-'.
The PCR method was performed essentially as described
by Whitcomb et al. (1989). Fifty to 100 ng of each cellular
DNA sample was added to aliquots of the amplification
solution consisting of 50 mM Tris-HCl (pH 8.3), 50 mM KCI,
7 mM MgC12, 170,ug ml-' BSA, 10 mM 2-mercapto-ethanol
and dATP, dCTP, dTTP, dGTP, each at 1.2mM.
Primer pairs (12.51tg ml-') were added to a final concen-
tration of 6 pmoles. After denaturation (94°C for 4 min),
samples were cooled and Taq-polymerase (Cetus, 1 unit)
added. Samples were subjected to 30 cycles of amplification
(1 min at 89°C, followed by 1 min at 63°C) using a Perkin-
Elmer Cetus DNA Thermal Cycler.
Amplified products of each sample (8 sl aliquots) were
electrophoresed on agarose gels (2%) and the gels then
stained with ethidium bromide for visualisation of amplified
DNA sequences which were subsequently blotted onto nylon
membranes. Hybridisation of these Southern blots were per-
formed using stringent conditions and the respective HPV
DNA (8 kb genome) as radiolabelled probe. Washing of the
blots was done using the same conditions. Each sample was
tested for the four HPV DNAs in four separate amplification
reactions.
Herpes simplex virus
The assay for HSV type specific antibodies was done by
microtest-plate ELISA using the general technical principles
described by Vestergaard (1986). Each serum was inves-
tigated by indirect blocking ELISA (Vestergaard &
Grauballe, 1979), and competitive ELISA (Najem et al.,
1983). The type-specificity of the competitive ELISA was
improved by additional blocking of HSV-type-common
epitopes with type-heterologous rabbit immunoglobulins
before competition.
Statistical analyses
To describe the variation in prevalence of possible risk fac-
tors of cervical cancer between Denmark and Greenland,
prevalence odds ratios were used. Using prevalence risk
ratios would intuitively be more straightforward but we need
to standardise for age since the age distribution differs
between Denmark and Greenland. The odds ratio has better
statistical properties and is usually considered to be a more
stable measure than the risk ratio. The age standardised odds
ratio was calculated by fitting the logistic model with country
as response variable and age (in 5-year age groups) and the
factor in question as explaining factors.
For evaluating the dependency between HPV and other
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genital infections and number of sexual partners, the odds
ratio was calculated separately for Denmark and Greenland,
this time with the infection in question as response variable
in the logistic model and number of partners as the explain-
ing factor.
Results
A total of 22 women (17.5%) from Nyk0bing Falster, and 21
women (16.3%) from Nuuk/Godthab had never previously
had a smear. The results of the smears taken at enrolment in
the study were nearly identical in the two areas. In Green-
land, seven women (5.4%) had abnormal smear (four atypia,
one mild dysplasia and two moderate dysplasia). In Den-
mark, an abnormal smear was found in six women (4.8%)
(three atypia, and three mild dysplasia).
Human papillomavirus infection
In Table II the overall prevalence of HPV as detected by
ViraPap and ViraType is shown. In Denmark, the detection
rate (ViraPap) was 4.8% and a similar prevalence (3.9%) was
found in Greenland. No significant difference was observed
between Denmark and Greenland concerning the frequency
of the specific HPV types. Not all ViraPap positives were
positive also by ViraType (and vice versa). The prevalence of
Danish women who were ViraPap and/or ViraType positive
was a little higher (6.3%) compared to Greenlandic women
(3.9%), but the difference was not statistically significant
(P = 0.36).
The results of the PCR test by intensity of signal (any
HPV type) are presented in Table III. The frequency of
women positive to any HPV type (defined as positivity to at
least one of the HPV types 11, 16, 18 and 33) was 38.9% in
the Danish population and 43.4% in the Greenlandic, the
age-standardised prevalence odds ratio (Greenland/Denmark)
being 1.3 (95% CI 0.8-2.1). However, when the intensity of
the positive signal was considered, a significant difference
between the two areas emerged. The rate of women with a
signal strength of 1-3 + (<1 HPV genome copy per cell)
was 15.9% among Danish women in contrast to 28.7% in
women from Greenland. The prevalence odds ratio (Green-
land/Denmark) was 2.3 (95% CI 1.2-4.4) when adjustment
was made for age. Conversely, a stronger positive signal
(G 4 + ) (> 1 HPV genome copy per cell) tended to be more
prevalent in women from Nyk0bing Falster (23.0%) com-
pared to women from Nuuk/Godthab (14.7%).
Table IV shows the age-standardised prevalence odds
ratios (Greenland/Denmark) of specific HPV types diagnosed
by means of PCR. The HPV 16 detection rate was higher in
Denmark (24.6%) than in Greenland (20.2%) and a similar
pattern was seen for HPV 18 (Denmark: 19.8% and Green-
land: 14.7%). However, none of these differences were statis-
tically significant. HPV 11 seemed to be a little more
prevalent in Greenland (6.2%) compared to Denmark
(3.2%), whereas the frequency of HPV 33 infection was
nearly identical in the two areas. The most pronounced
difference was found in the prevalence of women with multi-
ple HPV infections which was around 60% lower in Green-
land compared to Denmark (P = 0.03), when adjustment was
Table III Results of PCR test (any HPV)a by intensity of signal in
women from Nyk0bing Falster (Denmark) and Nuuk (Greenland)
1988
Area
Denmark
Greenland
Age-standardised
prevalence
odds ratio
Greenland/Denmark
(95% CI)
Total
Positive
n (%)
49 (38.9)
56 (43.4)
1.3
(0.8-2.1)
Intensity ofpositive signal
1-3+ >4+
n (%) n (%)
20 (15.9) 29 (23.0)
37 (28.7) 19 (14.7)
2.3 0.6
(1.2-4.4) (0.3-1.3)
aDefined as positivity to at least one ofthe HPV types 11, 16, 18 and
33.1-3 +: <1 HPV genome copy per cell. > 4 +: > 1 HPV genome
copy per cell.
Table IV Prevalence and age-standardised prevalence odds ratio of
specific HPV types as defined by PCR in Greenland and Denmark,
1988
Age-standardised
prevalence odds ratio
n (%) Greenland/Denmark (95% CI)
HPV 16 D' 31 (24.6)
Gb 26 (20.2) 0.8 (0.4-1.4)
HPV 18 D 25 (19.8)
G 19 (14.7) 0.7 (0.4-1.3)
HPV 33 D 11 (8.7)
G 12 (9.3) 1.1 (0.5-2.7)
HPV 11 D 4 (3.2)
G 8 (6.2) 2.1 (0.6-7.2)
Multiplec D 18 (14.3)
HPV G 8 (6.2) 0.4 (0.2-0.9)
infections
D = Denmark. bG= Greenland. CAlso included in other relevant
groups.
made for age. None of the HPV results changed when
previous smear history (ever/never) was included in the statis-
tical model.
In Figure 1, the HPV 16 age-curves for Denmark and
Greenland are shown. In Denmark, an overall decreasing
trend was observed with age. A similar tendency was seen in
Greenlandic women except for those being 35-39 years of
age, where the prevalence seemed to increase. However, the
prevalence estimates were based on very small numbers.
In Figure 2, the HPV results of the first Greenland/
Denmark study from 1986 as well as the second study from
1988 are presented schematically. The level of detection
seemed to be rather different for the three different methods
used. By PCR, we detected the highest rate, by filter in situ
hybridisation it was lower, and by ViraPap/ViraType we
observed the significantly lowest rate. However, the relation-
ship between the detection rates in Denmark and Greenland
was the same, independently of the detection method. Also
the frequency distribution of specific types was identical in
the two study areas from method to method.
Table II Prevalence ofHPV infection as defined by ViraPap and ViraType in Nyk0bing Falster
(Denmark) and Nuuk (Greenland), 1988
ViraPap and/or
ViraPap ViraType ViraType ViraType ViraType
positive 6/11 16/18 31/33/35 positive
Area n (%) n (%) n (%) n (%) n (%)
Denmark 6 (4.8) 0 - 3 (2.4) 4 (3.2) 8 (6.3)
Greenland 5 (3.9) 0 - 1 (0.8) 3 (2.3) 5 (3.9)
Difference in NSb NS NS NS NS
prevalence
odds ratioa
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Table V Comparison of prevalence rates of HSV infectionsa in
Greenlandic and Danish women in the first (1986)b and in the second
(1988) study
Denmark Greenland
1. study 2. study 1. study 2. study
Type of (1986) (1988) (1986) (1988)
infection n (%) n (%) n (0) n (0)
HSV 1 295 (76.0) 85 (67.5) 381 (97.7) 126 (97.7)
HSV 2 120 (30.9) 33 (26.2) 266 (68.2) 98 (76.0)
No HSV 84 (21.7) 36 (28.6) 4 (1.0) 0 (0.0)
aDefined bydetection oftype-specific HSVantibodies(ELISA).bOnly
a random subsampleof388 Danish women and 390Greenlandic women
were investigated for HSV antibodies.
0
20-24 25-29 30-34
Age (years)
35-39
Figure I Age-specific prevalence rates of human papillomavirus
type 16 detection (by PCR) in Greenlandic and Danish women,
20-39 years of age.
Herpes simplex virus infection
Table V presents a comparison of prevalence rates of HSV
infection diagnosed in the first and in the second Greenland/
Denmark study. In both areas, the results from the two
studies were very similar. Among Danish women, 67.5% had
antibodies for HSV 1 compared to 97.7% of the Greenlandic
women (P<0.0001). Concerning HSV 2, 26.2% of women in
Denmark had antibodies against this virus, while this was the
case for 76.0% of the women from Greenland (P<0.0001).
In Denmark, 36 women (28.6%) had no antibodies at all,
while no Greenlandic women belonged to this category
(P < 0.0001 ).
Self-reported venereal infections
The prevalences of a history of selected sexually transmitted
infections are shown in Table VI. The most substantial
difference between the areas was observed for gonorrhoea,
where 3.2% of the Danish women reported to have ever had
this disease in contrast to 86.0% of the women in Greenland.
About one fourth of the Greenlandic women had previously
had syphilis, while this was the case for none of the women
30
20
a)
u
from Denmark. Also internal genital inflammation and
genital herpes infection were significantly more frequent
among the Greenlandic participants, the prevalence odds
ratio (Greenland/Denmark) being respectively 5.0 (95% CI
2.9-8.5), and 8.7 (95% CI 2.0-37.5). By contrast, no
significant difference was found in the prevalence of an
episode of genital warts. The rate was 1 1.6% and 8.7% for
Greenland and Denmark, respectively (P = 0.30).
Other potential riskfactors
We also re-investigated the pattern of other suspected risk
factors for cervical cancer in the two populations. Table VII
presents a comparison of the findings of the two studies in
Greenland and Denmark. In the second study, a total of
14.0% of women in Greenland reported first coitus before
the age of 14 in contrast to 2.4% of the Danish women
(P = 0.001). The prevalence of women with .20 sexual part-
ners was 61.2% in Greenland and 3.2% in Denmark
(P<0.0001). Respectively, 91.5% and 52.4% of the Green-
landic and Danish women reported to be current smokers
(P<0.0001). The use (ever) of oral contraceptives was
reported more frequently among Danes (88.9%) than among
female Greenlanders (56.6%) (P<0.0001). The differences
found in the first study were thus confirmed. Although the
prevalence of ever use of condom in Greenland nearly
doubled from 1986 (18.1%) to 1988 (39.5%), it was still
significantly lower than in Denmark (61.1%) (P=0.001).
PCR
ViraPap/
ViraType FISH
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HPV HPV ViraPap HPV HPV HPV HPV
6/11 16/18 and/or 1 1 16 18 33
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_~ Denmark II Greenland
Figure 2 Prevalence of human papillomavirus (HPV) by different-detection methods in Greenlandic and Danish women, 20-39
years of age.
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Table VI Prevalence rates and prevalence odds ratios of history of selected genital infections in
Greenlandic and Danish women 20-39 years of age, 1988
Prevalence
Denmark Greenland odds ratio
Variable n (%) n (%) (Greenland/Denmark) (95% CI)
Internal genital inflammation
ever 32 (25.4) 81 (62.8) 5.0 (2.9-8.5)
Gonorrhoea
ever 4 (3.2) 111 (86.0) 186.8 (64.5-540.9)
Syphilis
ever 0 31 (24.0)
Genital herpes
ever 2 (1.6) 16 (12.4) 8.7 (2.0-37.5)
Genital warts
ever 11 (8.7) 15 (11.6) 1.4 (0.6-3.1)
Table VII Comparison ofprevalence rates ofselected characterstics ofGreenlandic and Danish
women in the first (1986) and the second (1988) study
Denmark Greenland
1. study (1986) 2. study (1988) 1. study (1986) 2. study (1988)
(n=661) (n= 126) (n=586) (n= 129)
Characteristic (% ofn) (% ofn) (% ofn) (% ofn)
Age at first intercourse
(years)
13 3.5 2.4 13.0 14.0
>20 9.2 8.7 0.9 0.0
Number of sexual
partners
0-1 20.4 23.0 1.7 0.0
>20 3.6 3.2 53.2 61.2
Current smoker 53.6 52.4 87.4 91.5
Oral
contraceptives
(ever) 87.9 88.9 51.2 56.6
Condom
(ever) 53.9 61.1 18.1 39.5
HPV and other genital infections in relation to number of
sexualpartners
In our previous Greenlandic study, women with 'multiple'
partners revealed a significantly lower risk of HPV detection
(HPV 16/18, HPV 6/11) than did women with 'few' partners.
In contrast, the risk for HSV-2 was highly associated with
increasing number of sexual partners (Kjaer et al., 1990). In
view of this we also found it of interest in the present study
to see how number of sexual partners did correlate to the
risk for HPV detection and HSV infection.
When HPV was detected by PCR, no association between
the risk of being infected (any HPV) and number of partners
was observed (Table VIII). This was also seen when only
women with a strong positive signal (>4 + ) were con-
sidered. Neither when HPV infection was assessed by
ViraPap/ViraType was there an association. We observed a
tendency of an increasing risk connnected with the presence
of HSV-2 and HSV-1 antibodies in relation to number of
sexual partners, although it did not reach statistical
significance.
When the self-reported venereal diseases were related to
number of sexual partners, we found an increasing risk for
all the diseases in both areas except for at history of genital
warts among Greenlandic women (Table IX).
Discussion
Human papillomavirus infection
This population-based study in which ViraPap/ViraType and
the PCR method have been used for HPV DNA detection,
reveals no statistically significant differences between Den-
mark and Greenland concerning the rate of HPV infection in
women 20-39 years of age. The prevalence of women
positive to ViraPap and/or ViraType is 1.6 times higher in
Denmark (6.9%) than in Greenland (3.9%). In light of the
low prevalence and because some of the positive signals were
Table VIII Odds ratios for anya human papillomavirus (HPV)
infection and Herpes simplex virus (HSV)b infection associated with
number of sexual partners
No. of Prevalence
positive/negative odds ratio (95% CI)
No. of sexual Any HPV
partners (Denmark)
0-1 12/17 1.0
2-3 11/16 1.0 (0.3-2.8)
4-9 18/34 0.8 (0.3-1.9)
>10 8/10 1.1 (0.4-3.7)
trend: P = 0.85
No. of sexual
partners (Greenland)
0-9 11/17 1.0
10-14 5/7 1.1 (0.3-4.4)
15-24 13/15 1.3 (0.5-3.9)
25-34 10/11 1.4 (0.5-4.4)
>35 17/23 1.1 (0.4-3.1)
trend: P = 0.91
No. of sexual HSV-2
partners (Denmark)
0-2 11/36 1.0
3-9 16/45 1.2 (0.5-2.8)
>10 6/12 1.6 (0.5-5.3)
trend: P = 0.45
No. of sexual
partners (Greenland)
0-9 20/7 1.0
10-24 29/11 0.9 (0.5-2.8)
>25 49/11 1.6 (0.5-4.3)
trend: P = 0.42
No. of sexual HSV-lc
partners (Denmark)
0-2 30/17 1.0
3-9 42/19 1.3 (0.6-2.8)
>10 13/5 1.5 (0.5-4.8)
trend: P = 0.48
'DefinedaspositivitytoatleastoneoftheHPVtypes 11, 16, 18and 33
as detected by the polymerase chain reaction (PCR) method. bDefined
by detection of type-specific HSV antibodies (ELISA). cOnly Danish
estimates because only one woman was without the disease in
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Table IX Odds ratios for selected self-reported sexually transmitted
diseases associated with number of sexual partners
Prevalence
Ever/Never odds ratio (95% CI)
No. of sexual Gonorrhoeaa
partners (Greenland)
0-9 18/10 1.0
10-14 10/2 2.8 (0.5-15.3)
15-29 33/5 3.7 (1.1-12.4)
30 50/1 27.8 (3.5-222)
trend: P = 0.0001
No. of sexual Syphilisa
partners (Greenland)
0-9 3/25 1.0
10-24 6/34 1.5 (0.3-6.5)
25-29 8/17 3.9 (0.9-16.9)
40 14/22 5.3 (1.3-20.9)
trend: P= 0.002
No. of sexual Genitala
partners herpes
(Greenland)
0-9 1/26 1.0
10-14 2/10 5.2 (0.4-62.3)
15 13/76 4.5 (0.6-34.7)
trend: P = 0.15
No. of sexual Genital
partners warts
(Denmark)
0-4 2/67 1.0
5-9 4/35 3.8 (0.7-21.1)
10-14 2/7 9.6 (1.2-76.1)
15 3/6 16.7 (2.4-116)
trend: P = 0.002
(Greenland)
0-9 4/23 1.0
10- 19 3/19 1.0 (0.2-4.8)
20-34 2/37 0.3 (0.1-1.9)
35 6/34 1.1 (0.3-4.2)
trend: P = 0.89
aOnly Greenlandic estimates because of too few persons with the
disease in Denmark.
weaker than the positive controls included in the commercial
kit, the material was sent to Dr A.T. Lorincz at Life Tech-
nologies, Inc., Gaithersburg, USA, who reviewed all the
ViraPap and ViraType filters:' The results of this review were
in agreement with the results presented here. The prevalence
of HPV (around 5%) detected by this method in both areas,
has also been found among women in Spain and Colombia
(N. Munoz & F.X. Bosch; personal communication). How-
ever, several investigations including our own previous com-
parison between Denmark and Greenland indicate a higher
prevalence of HPV in the general population when using
other HPV detection methods.
The results of the PCR test show that the frequency of any
HPV detection is a little higher in Greenland (43.4%) com-
pared to Denmark (38.9%). However, the prevalence of HPV
infections yielding a strong positive signal (>4+) is 1.6
times higher in Danish women (23.0%) than in Greenlandic
women (14.7%), and vice versa with the weak signal. This
could suggest that immune suppression is occurring in
women from Greenland, presumably because ofhigh levels of
exposure to HPV from sexual contact.
Thus, the results of both diagnostic methods (ViraPap/
Type and PCR) are in line with our previous population-
based cross-sectional study, in which we found a 1.5 times
higher prevalence of HPV 16/18 in Denmark compared to
Greenland using filter in situ hybridisation. Although the
overall level of the HPV detection rate is different for the
various hybridisation methods, the interrelationship between
Denmark and Greenland is consistent and independent of the
diagnostic method used. Nor does the inclusion of analysis
for HPV types 31/33/35 reveal a difference between the two
areas. Hypothetically, HPV DNA detection may have
different implications in the two areas. In Denmark it may
reflect transient, newly acquired infection, whereas in Green-
land it may be more indicative of chronic persistent infection.
Results from an analysis of HPV detectability in relation
to number of recent partners (i.e. partners in the last month)
may suppoort this hypothesis (Table X). The odds for having
HPV 16 or any HPV type detected in the case of no sexual
partners in the last month was respectively 3.2 and 5.6 times
higher in Greenland than in Denmark. By contrast, the HPV
detectability was similar in the two areas among women with
> 1 sexual partner in the last month.
However, apart from this it cannot be excluded that mis-
classification of HPV infection has influenced our results.
Recently, Franco (1991) has discussed the role of mis-
classification and has concluded that even low levels of such
a misclassification may lead to substantially erroneous
estimates of the HPV prevalence. DNA hybridisation
methods are currently the best diagnostic tool for detection
of HPV shedding. The sensitivities of dot blot hybridisation
and filter in situ hybridisation have been compared (Cor-
nelissen et al., 1988). Several studies have also compared the
filter in situ method with Southern blot hybridisation
(Schneider et al., 1986; de Villiers et al., 1987; Caussy et al.,
1988; Melchers et al., 1988). However, findings from these
comparisons are equivocal. Also studies using Southern blot
have reported rather heterogenous HPV prevalence rates and
also interlaboratory variability has been demonstrated even
between experienced laboratories (Brandsma et al., 1989). It
can be concluded that although studies comparing methods
are beginning to appear, we still know only little about the
validity of the tests in terms of ability to categorise truly
infected individuals as test-positive and non-infected as
negative.
Amplification of the viral genome through a polymerase
chain reaction is thought to be the most sensitive method for
the detection of HPV. However, the estimates of HPV
prevalence in normal women has varied from 0% to around
70% (Young et al., 1989; van den Brule et al., 1989; Manos
et al., 1990). One of the most substantial problems in this
field has been the risk of laboratory contamination. The lack
of geographical difference in HPV prevalence rates is not
likely to be explained by specific contamination of e.g.
especially the Danish samples, as the biological material was
collected by identical techniques in the two localities and as
all samples from both areas were received at the same time in
the laboratory with samples only marked by random study
numbers. Furthermore, to reduce the possibility of con-
tamination in the laboratory, the amplification solution was
prepared in large quantities and subsequently aliquoted for
single samples. The respective HPV primer pairs were added
and all aliquots frozen at - 200C until used. After randomly
TableX PrevalenceandprevalenceoddsratioofHPVasdefinedbyPCRinrelationtonumber
of recent partners in Greenland and Denmark, 1988
No of Prevalence
partners Denmark Greenland odds ratio
in last month n (%) n (%) Greenland/Denmark (95% CI)
HPV 16 (PCR):
0 2 (12.5) 5 (31.3) 3.2 (0.5-19.6)
>,1 29 (26.6) 21 (18.5) 0.6 (0.3-1.2)
ANY HPV (PCR):
0 3 (18.8) 9 (56.3) 5.6 (1.1-27.5)
> 1 46 (42.2) 47 (41.5) 1.0 (0.6-1.7)836 S.K. KJAER et al.
selecting a number of frozen aliquots, these solutions were
tested for the presence of contaminating HPV DNA.
Otherfactors
In contrast to HPV detection, the seroprevalence of HSV is
significantly higher in Greenlandic women compared to
women from Denmark, and the results from both areas are
very similar to the results obtained in the previous
Greenland/Denmark study (Kjaer et al., 1988).
There is also a high degree of consistency in the prevalence
of different sexual, contraceptive and smoking habits inside
each area from survey to survey. Greenlandic women have
significantly more sexual partners, earlier sexual debut, use
barrier contraceptives less frequently, and are more often
current smokers than Danish women. This pattern correlates
well with the observed high incidence of cervical cancer in
Greenland.
The prevalence of self-reported histories of internal genital
inflammation, gonorrhoea, syphilis and genital herpes infec-
tion is substantially higher in Greenland. This finding is
consistent with the high incidence of syphilis and gonorrhoea
in Greenland (Report from the Chief Medical Officer for
1989). By contrast, we do not find a statistically significant
difference in the rate of previous genital warts among the
women in the two areas. This is surprising in view of the
observed difference concerning the other self-reported sex-
ually transmitted diseases, but it is in line with the results of
the DNA hybridisation tests.
HPV and other genital infections in relation to number of
sexualpartners
The previously reported lack of relationship between sexual
activity in terms of number of sexual partners and the risk of
detection of HPV by filter in situ hybridisation (Kjaer et al.,
1990) is also found when PCR is used as the diagnostic
method. Although these findings are conforming to those of
early hybridisation studies (Villa et al., 1989; Reeves et al.,
1989; Kiviat et al., 1989), it is still somewhat surprising in
view of the general idea of HPV being mainly a sexually
transmitted disease. The possibility of a non-sexual transmis-
sion cannot be excluded. However, it is noteworthy that
some more recent hybridisation studies tend to find a clear
correlation between HPV DNA detection and number of
sexual partners (Ley et al., 1991). It cannot be excluded
either that unknown factors interfere with the expression of
HPV or with the ability of the hybridisation methods to
detect HPV in women with multiple sexual partners who
have for example other genital infections. On the other hand,
one might then have anticipated a correlation between HPV
detection and sexual covariates in the low risk area. It has
been suggested that persistence of HPV DNA may be cur-
tailed by the immune system and therefore some tests could
be negative irrespectively of other conditions including
number of partners. However, in the case of such a sensitive
test like PCR, one would expect that the residual HPV DNA
would be detectable and hence correlate with number of
sexual contacts to a higher degree than in the case of less
sensitive tests.
An alternative explanation for the lack of association
could also be that the answers to the sexual questions are not
valid. However, this is not likely to be the case in this study.
The information on sexual habits and HPV diagnosis were
gathered independently, and thus the interviewers had no
knowledge about the infection status of the women. Further-
more, the high consistency in the results from the first and
second survey dealing with two independent, randomly
chosen population-samples also speak against a pronounced
misclassification of the women regarding number of partners.
An indirect support for the validity is that number of
sexual partners is highly correlated with a self-reported his-
tory ofgonorrhoea, syphilis and genital herpes. Also the risk
of a previous episode ofgenital warts is related to number of
partners in Danish women, while no association is observed
among Greenlanders. This could be due to underreporting/
recall bias among Greenlandic women with'multiple' part-
ners. Alternatively, being submitted to different venereal
diseases, as well as multiple partners, a different immuno-
logical status could be expected in the Greenlandic women
which could suppress HPV viral replication and therefore
virus shedding, rendering the absence of genital warts as well
as the negative results obtained with the method used for
detection.
Conclusion
In conclusion, the lack of difference in HPV detection rates
between Denmark and Greenland is found independently of
whether filter in situ hybridisation, dot blot hybridisation
(ViraPap/ViraType) or PCR is used. Furthermore no rela-
tionship is seen between risk for HPV infection and number
of sexual partners for any of the diagnostic methods. By
contrast, substantial differences are observed between Green-
land and Denmark with regard to HSV infection, and other
cervical cancer risk factors. This confirmation of the previous
finding of no correlation between the level of HPV detection
in the female population and the incidence of cervical cancer
and also the surprising lack of association with number of
sexual partners could possibly be explained by the existence
of factors, especially in women with high sexual activity,
which interfere with the expression of the HPV infection. The
unexpected similarity in the rates of self-reported genital
warts in the two areas may support this. Additional strength
to this hypothesis is provided by the fact that genital warts is
the only self-reported venereal disease that does not correlate
with sexual activity in terms of number of sexual partners
(only among Greenlanders). Alternatively, there could exist
factors like e.g. other genital infections and oral contracep-
tive use, which interfere with the ability of the tests to detect
HPV DNA.
In order to assess if it is a genuine test problem or if there
exist such factors which interfere with the HPV expression or
the ability to detect the virus, it is ofhigh priority that future
research establishes the validity and overall qualification of
the different tools for HPV detection. At the time being we
measure both recurrent and new infections together without
knowing the clinical implications. By using DNA hybridisa-
tion technique, only temporal HPV virus shedding is
measured, indicating that a negative result does not exclude
the possibility of a latent infection. Thus it should be under-
lined that HPV DNA detection is definitely something
different from serological measurements, which ideally give
information about lifetime exposure. This leads to an alterna-
tive hypothesis suggesting that ecological studies may be
more sensitive to cumulative exposures as is the case with e.g.
seroprevalence of HSV-2, lifetime number of sexual partners
and lifetime smoking than HPV prevalence. HPV detection
rates are based on testing of single samples and do not reflect
cumulative exposure to the virus. It has been shown that
HPV positivity may vary on repeated testing. It is thus a
possibility that detectable HPV shedding may be less
associated with risk of cervical neoplasia than persistent
infections. A still unanswered question is the prevalence of
HPV in the cancers actually found in the two areas. This will
be an important issue for future research. Finally, maybe the
further development of suitable HPV serological methods
will give us a new and advantageous starting point in the
process of understanding the role of HPV in cervical car-
cinogenesis.
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